What happened, in summary

This report described 2 postmenopausal women with aggressive ER-negative, HER2-negative grade III infiltrating ductal breast cancer. One woman was 58 with a 5.5 cm breast tumor, and the other was 54 with a 2.4 cm tumor. Both had pathological lymph-node involvement, and both later died after metastatic dissemination through the lymphatic system. The clinical archive did not record systemic anticancer therapy before metastatic progression, so the case is mainly useful for understanding tumor biology rather than comparing treatment outcomes. The article focused on NUB1, a protein being studied as a possible marker of breast cancer progression. In the primary tumors, both women had low cytoplasmic NUB1 and high nuclear NUB1 staining. In metastatic tissue, NUB1 expression was completely lost in both the nucleus and cytoplasm. The 58-year-old woman remained relapse-free for 532 days after primary biopsy, while the 54-year-old woman had relapse-free survival recorded as 394 days after diagnosis and 590 days after primary biopsy. Both ultimately died from metastatic breast cancer. The patient-facing message is that these were high-risk, node-positive ER-negative breast cancers with fatal lymphatic spread, and the paired tissue analysis suggested that loss of NUB1 in metastases may be linked with tumor evolution, immune evasion, and poor prognosis. For visitors, the story is less about a named therapy and more about why some ER-negative breast cancers progress aggressively despite being evaluated through routine pathology. It also explains why paired primary and metastatic tissue can reveal changes that are invisible when only the original breast tumor is studied. The outcome is best framed respectfully as in memory, because both women died from metastatic breast cancer.